CU23769B7 - Derivados de piridazinil como inhibidores de smo - Google Patents

Derivados de piridazinil como inhibidores de smo

Info

Publication number
CU23769B7
CU23769B7 CU20090159A CU20090159A CU23769B7 CU 23769 B7 CU23769 B7 CU 23769B7 CU 20090159 A CU20090159 A CU 20090159A CU 20090159 A CU20090159 A CU 20090159A CU 23769 B7 CU23769 B7 CU 23769B7
Authority
CU
Cuba
Prior art keywords
piridazinil
derivatives
smo inhibitors
formula
smo
Prior art date
Application number
CU20090159A
Other languages
English (en)
Other versions
CU20090159A7 (es
Inventor
Naeem Yusuff
Stefan Peukert
Lawrence Blas Perez
Karen Miller-Moslin
Michael A Mcewan
Luis Llamas
John Lei
Joseph Kelleher Iii
Rajesh Karki
Rishi Kumar Jain
Feng He
Miao Dai
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39472520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU23769(B7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CU20090159A7 publication Critical patent/CU20090159A7/es
Publication of CU23769B7 publication Critical patent/CU23769B7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente divulgación se refiere a derivados de piridazinil relacionados con el diagnóstico y el tratamiento de patologías en relación con la senda de Hedgehog, incluyendo, pero no limitándose a, la formación de tumor, cáncer, neoplasia y tratornos hiper-proliferativos no malignos, específicamente se refiere a los compuestos de la fórmula (I); ESPACIO PARA LA FÓRMULA donde R1, R2, R3, L, n, X y Y son como se describe en la invención.
CU20090159A 2007-03-15 2009-09-15 Derivados de piridazinil como inhibidores de smo CU23769B7 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89499107P 2007-03-15 2007-03-15

Publications (2)

Publication Number Publication Date
CU20090159A7 CU20090159A7 (es) 2011-04-26
CU23769B7 true CU23769B7 (es) 2012-02-15

Family

ID=39472520

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20090159A CU23769B7 (es) 2007-03-15 2009-09-15 Derivados de piridazinil como inhibidores de smo

Country Status (33)

Country Link
US (1) US8536168B2 (es)
EP (1) EP2137162B1 (es)
JP (1) JP5550352B2 (es)
KR (1) KR101473504B1 (es)
CN (1) CN101657430B (es)
AR (1) AR065718A1 (es)
AU (1) AU2008225766B2 (es)
BR (1) BRPI0809193A2 (es)
CA (1) CA2681162C (es)
CL (1) CL2008000754A1 (es)
CO (1) CO6220967A2 (es)
CR (1) CR11016A (es)
CU (1) CU23769B7 (es)
DK (1) DK2137162T3 (es)
DO (1) DOP2009000217A (es)
EA (1) EA016564B1 (es)
EC (1) ECSP099636A (es)
GE (1) GEP20125487B (es)
GT (1) GT200900244A (es)
IL (1) IL200654A (es)
MA (1) MA31258B1 (es)
MX (1) MX2009009873A (es)
MY (1) MY156814A (es)
NI (1) NI200900168A (es)
NZ (1) NZ579402A (es)
PE (1) PE20090188A1 (es)
SG (1) SG182205A1 (es)
SM (1) SMP200900082B (es)
TN (1) TN2009000373A1 (es)
TW (1) TWI406857B (es)
UA (1) UA100684C2 (es)
WO (1) WO2008110611A1 (es)
ZA (1) ZA200905949B (es)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
NZ579402A (en) 2007-03-15 2012-03-30 Novartis Ag Organic compounds for diagnosis and treatment of pathologies relating to the Hedgehog pathway
ES2499018T3 (es) 2007-09-20 2014-09-26 Irm Llc Compuestos y composiciones como moduladores de la actividad de GPR119
EP2224807B1 (en) 2007-12-27 2016-11-09 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
AR070479A1 (es) * 2008-02-26 2010-04-07 Takeda Pharmaceutical Derivado heterociclico fusionado y su uso
MX2010011948A (es) * 2008-04-29 2010-12-14 Lilly Co Eli Antagonistas de la trayectoria hedgehog de ftalazina disustituida.
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
CN102170873B (zh) * 2008-10-01 2014-07-30 诺华股份有限公司 用于治疗与hedgehog通路有关的病症的smoothened拮抗
EP2364185B1 (en) 2008-11-03 2013-05-22 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
AU2009314288B2 (en) * 2008-11-17 2013-05-02 Eli Lilly And Company Tetrasubstituted pyridazines hedgehog pathway antagonists
CA2743483C (en) * 2008-11-17 2014-03-11 Eli Lilly And Company Tetrasubstituted pyridazine hedgehog pathway antagonists
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
JP6141015B2 (ja) 2009-08-05 2017-06-07 インフィニティ ファーマスーティカルズ、インク． シクロパミン類似体の酵素によるアミノ基転移
US20110039850A1 (en) * 2009-08-12 2011-02-17 Mhairi Copland Leukemia Treatment
DK2470173T3 (en) * 2009-08-25 2016-06-06 Abraxis Bioscience Llc Combination therapy of nanoparticle composition of the taxane and the hedgehog inhibitors
CN102665700A (zh) * 2009-11-18 2012-09-12 诺瓦提斯公司 治疗实体瘤和其它恶性肿瘤的方法和组合物
CN103002738A (zh) 2010-05-21 2013-03-27 英特利凯恩有限责任公司 用于激酶调节的化学化合物、组合物和方法
AU2011261375B2 (en) 2010-06-04 2016-09-22 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
US9006450B2 (en) * 2010-07-01 2015-04-14 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
US9376447B2 (en) 2010-09-14 2016-06-28 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
US8809349B2 (en) 2011-01-10 2014-08-19 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
TWI565709B (zh) 2011-07-19 2017-01-11 英菲尼提製藥股份有限公司 雜環化合物及其用途
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG11201400310WA (en) 2011-08-29 2014-06-27 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
JP6129199B2 (ja) * 2011-12-02 2017-05-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピペリジン誘導体、その医薬組成物及び使用
ES2797123T3 (es) 2011-12-21 2020-12-01 Novira Therapeutics Inc Agentes antivirales para la hepatitis B
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN104902885A (zh) 2012-08-28 2015-09-09 爱尔兰詹森科学公司 氨磺酰基-芳基酰胺和其作为药物用于治疗乙型肝炎的用途
MX386085B (es) 2012-11-01 2025-03-18 Infinity Pharmaceuticals Inc Tratamiento de canceres utilizando moduladores de las isoformas de pi3 cinasa
CA2893133A1 (en) 2012-11-29 2014-06-05 Strasspharma Llc Methods of modulating follicle stimulating hormone activity
PL2961732T3 (pl) 2013-02-28 2017-09-29 Janssen Sciences Ireland Uc Sulfamoilo-aryloamidy i ich stosowanie jako leków do leczenia wirusowego zapalenia wątroby typu B
WO2014151386A1 (en) 2013-03-15 2014-09-25 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
EA027068B1 (ru) 2013-04-03 2017-06-30 Янссен Сайенсиз Айрлэнд Юси Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
CN105960400B (zh) 2013-05-17 2019-05-31 爱尔兰詹森科学公司 氨磺酰基噻吩酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
CA2914284A1 (en) 2013-05-30 2014-12-04 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
EP3357906B1 (en) 2013-07-25 2019-12-04 Janssen Sciences Ireland Unlimited Company Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
CN105793255B (zh) 2013-10-04 2018-11-16 无限药品股份有限公司 杂环化合物及其用途
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6452119B2 (ja) 2013-10-23 2019-01-16 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー カルボキサミド誘導体およびｂ型肝炎の処置のための医薬品としてのその使用
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
EP3094627B1 (en) 2014-01-17 2018-08-22 Novartis AG 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
JO3517B1 (ar) * 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
CN105899493B (zh) * 2014-01-17 2019-03-29 诺华股份有限公司 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物
US20150216938A1 (en) 2014-02-05 2015-08-06 Novira Therapeutics Inc. Combination therapy for treatment of hbv infections
HK1225389A1 (zh) 2014-02-06 2017-09-08 Janssen Sciences Ireland Uc 氨磺酰基吡咯酰胺衍生物及其作为药物用於治疗乙型肝炎的用途
MX382033B (es) 2014-03-19 2025-03-13 Infinity Pharmaceuticals Inc Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
WO2015160986A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN105985320B (zh) * 2015-02-11 2018-10-26 复旦大学 苄基酞嗪化合物及其制备方法和用途
CN105985319B (zh) * 2015-02-11 2019-02-26 复旦大学 芳基酞嗪化合物及其制备方法和用途
CN105985321B (zh) * 2015-02-11 2018-10-26 复旦大学 吡唑酞嗪化合物及其制备方法和用途
CA2980298A1 (en) 2015-03-19 2016-09-22 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis b infections
BR112017026103B1 (pt) 2015-06-04 2023-10-03 Sol-Gel Technologies Ltd Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos
WO2016203405A1 (en) 2015-06-19 2016-12-22 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
WO2016203404A1 (en) 2015-06-19 2016-12-22 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
US10287266B2 (en) 2015-06-19 2019-05-14 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
EP3356328A1 (en) 2015-09-29 2018-08-08 Novira Therapeutics, Inc. Crystalline forms of a hepatitis b antiviral agent
US20170231968A1 (en) 2016-02-11 2017-08-17 PellePharm, Inc. Method for relief of and treatment of pruritus
US10195283B2 (en) 2016-03-18 2019-02-05 R.P. Scherer Technologies, Llc Hydrazinyl-substituted heteroaryl compounds and methods for producing a conjugate
KR20180129943A (ko) 2016-04-15 2018-12-05 노비라 테라퓨틱스, 인코포레이티드 캡시드 조립 억제제를 포함하는 배합물 및 방법
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR102457146B1 (ko) 2016-06-14 2022-10-19 노파르티스 아게 Shp2의 활성을 억제하기 위한 화합물 및 조성물
RU2754507C2 (ru) 2016-06-24 2021-09-02 Инфинити Фармасьютикалз, Инк. Комбинированная терапия
CA3048340A1 (en) 2017-01-10 2018-07-19 Novartis Ag Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor
ES2924933T3 (es) 2017-10-27 2022-10-11 Boehringer Ingelheim Int Derivados de piridina y usos terapéuticos de los mismos como inhibidores de TRPC6
DE102018105524A1 (de) * 2018-03-09 2019-09-12 Universität Duisburg-Essen Verwendung von Modulatoren der Sphingosin-1-phosphat-Signaltransduktion
MA52019A (fr) 2018-03-14 2021-01-20 Janssen Sciences Ireland Unlimited Co Schéma posologique de modulateur d'assemblage de capside
CN112384503A (zh) * 2018-07-02 2021-02-19 洛桑联邦理工学院(Epfl) 乳酸增强化合物及其用途
CN108997224B (zh) * 2018-08-28 2023-04-28 韶远科技（上海)有限公司 一种2-氯-5-氰基含氮六元杂环化合物的制备方法
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors
MX2021010145A (es) 2019-02-22 2021-09-14 Janssen Sciences Ireland Unlimited Co Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb.
EP3966205A1 (en) 2019-05-06 2022-03-16 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases
CN110845426A (zh) * 2019-11-29 2020-02-28 都创(上海)医药科技有限公司 一种2-氯-5-氰基嘧啶化合物制备方法
KR102394110B1 (ko) * 2020-01-22 2022-05-04 가톨릭대학교 산학협력단 신규 화합물 및 이의 용도
EP4229828A4 (en) 2020-10-13 2024-08-28 Endeavor Biomedicines, Inc. METHODS OF TREATMENT OF FIBROSIS
EP4074317A1 (en) 2021-04-14 2022-10-19 Bayer AG Phosphorus derivatives as novel sos1 inhibitors
CN116199625A (zh) * 2023-01-19 2023-06-02 上海昱菘医药科技有限公司 一种烟酸酯类化合物的制备方法
WO2025188802A1 (en) 2024-03-05 2025-09-12 Endeavor Biomedicines, Inc. Methods of improving lung function

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
US3668207A (en) * 1970-01-22 1972-06-06 Ciba Geigy Corp 2-amino-4-aryl-quinolines
DE2643753A1 (de) 1976-09-29 1978-04-06 Thomae Gmbh Dr K Neue 1h-pyrazolo eckige klammer auf 3,4-b eckige klammer zu pyridine
FR2421900A1 (fr) * 1977-03-17 1979-11-02 Sauba Lab Piperazino-3-indoles, leur procede de preparation et leurs applications therapeutiques
FI70411C (fi) 1980-12-29 1986-09-19 Pfizer Foerfarande foer framstaellning av nya antihypertensiva 4-amino-6,7-dimetoxi-2-piperazinokinazolin derivat
ZA852235B (en) * 1984-03-26 1986-11-26 Janssen Pharmaceutica Nv Anti-virally active pyridazinamines
EP0157037A3 (en) 1984-03-29 1986-11-05 Bowmar Instrument Corporation Long-stroke push-button switch
US4569934A (en) * 1984-10-09 1986-02-11 American Cyanamid Company Imidazo[1,2-b]pyridazines
CA1307786C (en) * 1984-12-14 1992-09-22 Keiichi Yokoyama Quinazoline derivatives and antihypertensive preparations containing same as effective components
US4760064A (en) * 1984-12-18 1988-07-26 Otsuka Pharmaceutical Co., Ltd. Carbostyril compounds, compositions containing same and processes for preparing same
JP2544939B2 (ja) * 1987-09-01 1996-10-16 大塚製薬株式会社 ベンゾヘテロ環誘導体
JPH02193992A (ja) 1989-01-23 1990-07-31 Kyowa Hakko Kogyo Co Ltd キナゾリン誘導体
JPH03106875A (ja) * 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd １―（３―ピリジルメチル）フタラジン誘導体
HU219864B (hu) 1994-08-09 2001-08-28 Eisai Co., Ltd. cGMP-PDE inhibitor kondenzált piridazinszármazékok és alkalmazásuk
JP3919835B2 (ja) * 1994-08-09 2007-05-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 縮合ピリダジン系化合物
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
US5859012A (en) * 1996-04-03 1999-01-12 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5935958A (en) * 1996-07-01 1999-08-10 Schering Corporation Muscarinic antagonists
EP1082308B1 (de) 1998-04-20 2009-04-01 Abbott GmbH & Co. KG Heterocyclisch substituierte amide als calpainhemmer
US6066636A (en) * 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists
IL140249A0 (en) * 1998-06-30 2002-02-10 Schering Corp Muscarinic antagonists
JP2002535365A (ja) * 1999-01-28 2002-10-22 ブリストル−マイヤーズ スクイブ カンパニー 抗うつ性複素環化合物
JP2000281660A (ja) 1999-03-29 2000-10-10 Sumitomo Pharmaceut Co Ltd キナゾリン誘導体
CN1221262C (zh) 1999-03-30 2005-10-05 诺瓦提斯公司 治疗炎性疾病的酞嗪衍生物
WO2000066558A1 (en) 1999-05-04 2000-11-09 Schering Corporation Piperazine derivatives useful as ccr5 antagonists
ES2165274B1 (es) * 1999-06-04 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de indolilpiperidina como agentes antihistaminicos y antialergicos.
ATE283700T1 (de) * 1999-06-08 2004-12-15 Lorantis Ltd Therapeutische verwendung eines inhibitors des hedgehog signalübertragungsweges
FR2803593B1 (fr) * 2000-01-06 2002-02-15 Sanofi Synthelabo Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant
DE60112272T2 (de) 2000-04-27 2006-05-24 Astellas Pharma Inc. Imidazopyridin-derivate
DE10043659A1 (de) 2000-09-05 2002-03-14 Merck Patent Gmbh Arylpiperazinderivate
ES2172436B1 (es) * 2000-10-31 2004-01-16 Almirall Prodesfarma Sa Derivados de indolilpiperidina como agentes antihistaminicos y antialergicos.
EP1353674A1 (en) 2000-12-29 2003-10-22 Alteon, Inc. Method for treating glaucoma ivb
SE0103754L (sv) 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
WO2002080952A2 (en) * 2001-04-09 2002-10-17 Lorantis Limited Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways
JP4929547B2 (ja) 2001-09-03 2012-05-09 コニカミノルタホールディングス株式会社 アゾメチン化合物、アゾメチン化合物と金属イオン含有化合物との混合物、感熱転写記録材料、カラートナー
ATE369854T1 (de) 2001-10-19 2007-09-15 Ortho Mcneil Pharm Inc 2-phenyl benzimidazole und imidazo-[4,5]-pyridine als cds1/chk2-inhibitoren und adjuvantien in der chemotherapie oder strahlungstherapie zur behandlung von krebs
MY138836A (en) * 2002-03-27 2009-07-31 Glaxo Group Ltd Quinoline derivatives and their use as 5-ht6 receptor ligands
JP2006509223A (ja) 2002-10-16 2006-03-16 エレクトロニクス アンド テレコミュニケーションズ リサーチ インスチチュート 使用者の視覚障害の特徴的症状及び再生嗜好によるビジュアル・コンテンツ適応変換方法及びシステム
KR20050106033A (ko) 2003-02-24 2005-11-08 아레나 파마슈티칼스, 인크. 글루코스 대사 조절제로서의 페닐- 및피리딜피페리딘-유도체
EP2316826A1 (en) * 2003-07-30 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutics agents
DE10337184A1 (de) * 2003-08-13 2005-03-10 Gruenenthal Gmbh Substituierte 3-Pyrrolidin-Indol-Derivate
JP5335191B2 (ja) * 2003-08-22 2013-11-06 デンドレオン コーポレイション Ｔｒｐ−ｐ８発現に関連する疾患の処置をするための組成物および方法
WO2005033288A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
AU2005249380C1 (en) 2004-04-23 2012-09-20 Exelixis, Inc. Kinase modulators and methods of use
KR20210090744A (ko) 2004-09-02 2021-07-20 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
GB0422263D0 (en) * 2004-10-07 2004-11-10 Glaxo Group Ltd Novel compounds
US7759337B2 (en) 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
DE102005023943A1 (de) 2005-05-20 2006-11-23 Grünenthal GmbH Pentafluorsulfanyl-substituierte Verbindung und deren Verwendung zur Herstellung von Arzneimitteln
CA2612227C (en) * 2005-06-14 2014-04-22 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
US8364148B2 (en) * 2005-07-07 2013-01-29 Qualcomm Incorporated Methods and devices for interworking of wireless wide area networks and wireless local area networks or wireless personal area networks
JP5225857B2 (ja) * 2005-11-14 2013-07-03 ジェネンテック，インコーポレイティド ヘッジホッグシグナル伝達のビスアミド阻害剤
CA2630884A1 (en) * 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
GB0602335D0 (en) * 2006-02-07 2006-03-15 Remynd Nv Thiadiazole Derivatives For The Treatment Of Neurodegenerative Diseases
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
CA2646958A1 (en) 2006-03-21 2007-09-27 Schering Corporation Heterocyclic substituted pyridine compounds with cxcr3 antagonist activity
CA2650704A1 (en) 2006-04-28 2007-11-08 Northwestern University Salts of pyridazine compounds
EP2063894B1 (en) 2006-04-28 2019-08-28 Northwestern University Formulations containing pyridazine compounds for treating neuroinflammatory diseases
WO2007127475A2 (en) 2006-04-28 2007-11-08 Northwestern University Pyridazines for demyelinating diseases and neuropathic pain
EP1849781A1 (en) * 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
AU2007272884A1 (en) * 2006-07-14 2008-01-17 Pharmacopeia, Inc. Heterocyclic substituted piperazine compounds with CXCR3 antagonist activity
GB0623258D0 (en) * 2006-11-22 2007-01-03 Remynd Nv Thiadiazole derivatives for the treatment of neuro-degenerative diseases
AU2007331723B2 (en) 2006-12-14 2013-05-30 Syngenta Limited 4-phenyl-pyrane-3,5-diones, 4-phenyl-thiopyrane-3,5-diones and cyclohexanetriones as novel herbicides
US20120157466A1 (en) 2006-12-22 2012-06-21 Qingbei Zeng Heterocyclic compounds with cxcr3 antagonist activity
TW200900391A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-phenyl-piperidin-1-yl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
CA2679985A1 (en) 2007-03-15 2008-09-18 F. Hoffmann-La Roche Ag Malonamides as orexin antagonists
NZ579402A (en) 2007-03-15 2012-03-30 Novartis Ag Organic compounds for diagnosis and treatment of pathologies relating to the Hedgehog pathway
CA2680583A1 (en) 2007-03-15 2008-09-25 Schering Corporation Pyridazinone derivatives useful as glucan synthase inhibitors
WO2009035568A1 (en) 2007-09-07 2009-03-19 Amgen Inc. Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling
GB0808888D0 (en) * 2008-05-15 2008-06-25 Syngenta Participations Ag Insecticidal compounds
EP2310374B1 (en) * 2008-07-03 2012-10-31 Janssen Pharmaceutica N.V. Substituted 6- (1-piperazinyl) -pyridazines as 5-ht6 receptor antagonists
US20100029655A1 (en) * 2008-07-11 2010-02-04 Martin Robert Leivers Processes For The Preparation Of Anti-Viral Compounds And Compositions Containing Them
EP2321298B1 (en) * 2008-08-04 2013-10-02 Amgen Inc. Aurora kinase modulators and methods of use
EP2364185B1 (en) * 2008-11-03 2013-05-22 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
FR2939134A1 (fr) * 2008-12-01 2010-06-04 Sanofi Aventis Derives de 6-cycloamino-3-(1h-pyrrolo°2,3-b!pyridin-4-yl) imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique
TWI520989B (zh) * 2015-03-02 2016-02-11 國立交通大學 製備高分子球的方法

Also Published As

Publication number Publication date
SG182205A1 (en) 2012-07-30
CU20090159A7 (es) 2011-04-26
NI200900168A (es) 2010-09-09
GT200900244A (es) 2010-03-15
JP2010521438A (ja) 2010-06-24
CO6220967A2 (es) 2010-11-19
NZ579402A (en) 2012-03-30
JP5550352B2 (ja) 2014-07-16
US8536168B2 (en) 2013-09-17
KR101473504B1 (ko) 2014-12-16
US20100069368A1 (en) 2010-03-18
DOP2009000217A (es) 2009-10-31
EP2137162B1 (en) 2018-08-01
ZA200905949B (en) 2010-10-27
PE20090188A1 (es) 2009-03-20
SMAP200900082A (it) 2009-11-06
AR065718A1 (es) 2009-06-24
DK2137162T3 (en) 2018-11-26
WO2008110611A1 (en) 2008-09-18
BRPI0809193A2 (pt) 2014-09-23
TN2009000373A1 (en) 2010-12-31
SMP200900082B (it) 2010-09-10
MX2009009873A (es) 2009-09-24
IL200654A0 (en) 2010-05-17
TW200848414A (en) 2008-12-16
CR11016A (es) 2009-10-06
CN101657430A (zh) 2010-02-24
IL200654A (en) 2015-03-31
KR20090121386A (ko) 2009-11-25
CA2681162A1 (en) 2008-09-18
CN101657430B (zh) 2013-05-01
EA016564B1 (ru) 2012-05-30
AU2008225766B2 (en) 2012-06-07
TWI406857B (zh) 2013-09-01
GEP20125487B (en) 2012-04-25
EA200901170A1 (ru) 2010-04-30
AU2008225766A1 (en) 2008-09-18
EP2137162A1 (en) 2009-12-30
MA31258B1 (fr) 2010-03-01
UA100684C2 (uk) 2013-01-25
ECSP099636A (es) 2009-10-30
CA2681162C (en) 2015-11-24
CL2008000754A1 (es) 2008-10-24
MY156814A (en) 2016-03-31

Similar Documents

Publication Publication Date Title
CU23769B7 (es) Derivados de piridazinil como inhibidores de smo
CR20110014A (es) Derivados de piridazina como inhibidores de smo
CY1124168T1 (el) Ετεροκυκλυλαμiνες ως αναστολεiς ρι3κ
UY32585A (es) Nuevos derivados del indazol utiles como inhibidores de la familia fosfoinositida 3´oh quinasa
EA201270373A1 (ru) Ингибиторы jak2 и их применение для лечения миелопролиферативных заболеваний и злокачественной опухоли
UY34451A (es) Derivados de uracilo como inhibidores de la quinasa axl y c-met
MA34064B1 (fr) Compose heterocyclique
CR11620A (es) Derivados de Imadazo-[1,2,b]-Piridazina para el Tratamiento de Enfermedad Mediada por Cinosa de Tirosina C-Met
MX2013012979A (es) Piridina y derivados de pirazina.
MX2015007097A (es) Nuevas fenil-piridinas/pirazinas bi-anulares para el tratamiento de cancer.
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
EA201200471A1 (ru) Простые эфирные производные бициклических гетероарилов
MX2012001413A (es) Compuestos azaheterociclicos novedosos.
ECSP11011245A (es) Novedosos herbicidas
EA201100296A1 (ru) Новые фениламино-изоникотинамидные соединения
EA201200087A1 (ru) 2-карбоксамиды циклоаминомочевин, которые являются ингибиторами pi3k
ECSP109998A (es) Nuevos herbicidas
NZ590076A (en) Treating plexiform neurofibroma and related tumors
HN2009001950A (es) Derivados de bencilo y piridinilo
GB2501403A (en) 3-Arylethynyl substituted quinazolinone compounds
CY1115457T1 (el) Παραγωγα τετραϋδρο-πυριδο-πυριμιδινης
TN2011000009A1 (en) Pyridazne derivatives as smo inhibitors

Legal Events

Date Code Title Description
FG Grant of patent